Sematrinity is indicated for type 2 diabetes and is available in two dose strengths, priced at 750 1,300 per week ( 3,000 to 5,200 per month)
Genetic therapy approaches for ornithine transcarbamylase deficiency
46 In studies evaluating the efficacy and safety of GLP-1 RAs, nausea emerged as the most frequently reported GI symptom, generally following a dose-dependent pattern, appearing during the first weeks of therapy, and decreasing as tolerance developed
Although high peripheral exposure may be required to obtain the fractional central exposure necessary to illicit a pharmacologic response, insufficient selectivity between MC1R and MC4R activity can lead to peripheral activation of MC1R (142, 143)
Cost Concerns The high cost of GLP-1 drugs, especially for weight loss purposes, is another driving factor behind the microdosing trend